A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
clinical trial results
endometrial cancer
gynecologic cancers
gynecologic oncology
immunotherapy/checkpoint blockade
phase 2 clinical trial
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
revised:
19
07
2021
received:
13
05
2021
accepted:
10
08
2021
pubmed:
8
12
2021
medline:
11
3
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) is a biomarker for responses to immune checkpoint inhibitors (ICIs). Whether mechanisms underlying microsatellite instability alter responses to ICIs is unclear. This article reports data from a prospective phase 2 pilot study of pembrolizumab in patients with recurrent MSI-H endometrial cancer (EC) analyzed by whole exome sequencing (WES) and potential mechanisms of primary/secondary ICI resistance (NCT02899793). Patients with measurable MSI-H/dMMR EC confirmed by polymerase chain reaction/immunohistochemistry were evaluated by WES and received 200 mg of pembrolizumab every 3 weeks for ≤2 years. The primary end point was the objective response rate (ORR). Secondary end points included progression-free survival (PFS) and overall survival (OS). Twenty-five patients (24 evaluable) were treated. Six patients (25%) harbored Lynch/Lynch-like tumors, whereas 18 (75%) had sporadic EC. The tumor mutation burden was higher in Lynch-like tumors (median, 2939 mutations/megabase [Mut/Mb]; interquartile range [IQR], 867-5108 Mut/Mb) than sporadic tumors (median, 604 Mut/Mb; IQR, 411-798 Mut/Mb; P = .0076). The ORR was 100% in Lynch/Lynch-like patients but only 44% in sporadic patients (P = .024). The 3-year PFS and OS proportions were 100% versus 30% (P = .017) and 100% versus 43% (P = .043), respectively. This study suggests prognostic significance of Lynch-like cancers versus sporadic MSI-H/dMMR ECs for ORR, PFS, and OS when patients are treated with pembrolizumab. Larger confirmatory studies in ECs and other MSI-H/dMMR tumors are necessary. Defective antigen processing/presentation and deranged induction in interferon responses serve as mechanisms of resistance in sporadic MSI-H ECs. Oligoprogression in MSI-H/dMMR patients appears salvageable with surgical resection and/or local treatment and the continuation of pembrolizumab off study. Clinical studies evaluating separate MSI-H/dMMR EC subtypes treated with ICIs are warranted.
Sections du résumé
BACKGROUND
Microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) is a biomarker for responses to immune checkpoint inhibitors (ICIs). Whether mechanisms underlying microsatellite instability alter responses to ICIs is unclear. This article reports data from a prospective phase 2 pilot study of pembrolizumab in patients with recurrent MSI-H endometrial cancer (EC) analyzed by whole exome sequencing (WES) and potential mechanisms of primary/secondary ICI resistance (NCT02899793).
METHODS
Patients with measurable MSI-H/dMMR EC confirmed by polymerase chain reaction/immunohistochemistry were evaluated by WES and received 200 mg of pembrolizumab every 3 weeks for ≤2 years. The primary end point was the objective response rate (ORR). Secondary end points included progression-free survival (PFS) and overall survival (OS).
RESULTS
Twenty-five patients (24 evaluable) were treated. Six patients (25%) harbored Lynch/Lynch-like tumors, whereas 18 (75%) had sporadic EC. The tumor mutation burden was higher in Lynch-like tumors (median, 2939 mutations/megabase [Mut/Mb]; interquartile range [IQR], 867-5108 Mut/Mb) than sporadic tumors (median, 604 Mut/Mb; IQR, 411-798 Mut/Mb; P = .0076). The ORR was 100% in Lynch/Lynch-like patients but only 44% in sporadic patients (P = .024). The 3-year PFS and OS proportions were 100% versus 30% (P = .017) and 100% versus 43% (P = .043), respectively.
CONCLUSIONS
This study suggests prognostic significance of Lynch-like cancers versus sporadic MSI-H/dMMR ECs for ORR, PFS, and OS when patients are treated with pembrolizumab. Larger confirmatory studies in ECs and other MSI-H/dMMR tumors are necessary. Defective antigen processing/presentation and deranged induction in interferon responses serve as mechanisms of resistance in sporadic MSI-H ECs. Oligoprogression in MSI-H/dMMR patients appears salvageable with surgical resection and/or local treatment and the continuation of pembrolizumab off study. Clinical studies evaluating separate MSI-H/dMMR EC subtypes treated with ICIs are warranted.
Identifiants
pubmed: 34875107
doi: 10.1002/cncr.34025
pmc: PMC9465822
mid: NIHMS1752713
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
pembrolizumab
DPT0O3T46P
Banques de données
ClinicalTrials.gov
['NCT02899793']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1206-1218Subventions
Organisme : Stand Up To Cancer
Organisme : NCI NIH HHS
ID : U01 CA176067
Pays : United States
Organisme : Fondazione Guido Berlucchi
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIH Clinical Center
ID : CA-16359
Organisme : Gilead Sciences
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Merck
Organisme : Honorable Tina Brozman Foundation
Organisme : National Research Foundation of Korea
ID : NRF-2019R1A4A102900
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 American Cancer Society.
Références
J Pathol. 2008 Jan;214(1):10-6
pubmed: 17973250
Fam Cancer. 2011 Sep;10(3):557-65
pubmed: 21598004
J Immunother Cancer. 2019 Jul 24;7(1):196
pubmed: 31340861
Hum Mutat. 2013 Jan;34(1):57-65
pubmed: 23033316
Am J Surg Pathol. 2011 Dec;35(12):1902-5
pubmed: 22067334
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21
pubmed: 23359684
Stat Med. 1998 Oct 30;17(20):2301-12
pubmed: 9819829
Cancer Res. 2001 Apr 1;61(7):2813-5
pubmed: 11306449
J Clin Oncol. 2006 Apr 10;24(11):1745-53
pubmed: 16549821
Mod Pathol. 2013 Jul;26(7):1013-22
pubmed: 23370766
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Oncol Lett. 2017 Sep;14(3):3297-3301
pubmed: 28927079
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Oncotarget. 2018 Jan 24;9(13):11046-11059
pubmed: 29541395
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
BMC Cancer. 2018 May 21;18(1):576
pubmed: 29783979
Ann Oncol. 2020 Sep;31(9):1115-1118
pubmed: 32771306
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Clin Cancer Res. 2017 Aug 1;23(15):4473-4481
pubmed: 28264871
Am J Hum Genet. 1999 Nov;65(5):1291-8
pubmed: 10521294
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Clin Cancer Res. 2018 Jul 15;24(14):3282-3291
pubmed: 29351920
Nature. 2019 Jan;565(7737):43-48
pubmed: 30559380
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Ann Oncol. 2021 Aug;32(8):1045-1046
pubmed: 33932502
Gynecol Oncol. 2020 Apr;157(1):161-166
pubmed: 31924334
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Bioinformatics. 2015 May 15;31(10):1536-43
pubmed: 25583119
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010
Oncogene. 2005 Jun 2;24(24):3995-8
pubmed: 15782118
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308